MTI

Minerals Technologies Announces Election of Kristina M. Johnson to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Master of Science, Electrical engineering, Ohio State University, I Squared Capital, State university system, Education, Duke University, University, Electricity, MTX, Senior, MTI, Mineral, Cisco, State, Stanford University, National academy, Johns Hopkins University, Computer, Government, Management

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.
  • “We are excited to welcome Kristina Johnson to our Board,” said Douglas T. Dietrich, Chairman and Chief Executive Officer.
  • She currently serves on the boards of DuPont and Cisco Systems, Inc., and previously served on the Minerals Technologies Inc. Board from 2000 to 2009.
  • Dr. Johnson will begin her service on the MTI Board of Directors on May 13, 2024.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

AgEagle Aerial Systems Appoints Seasoned Defense Industry Executive William Irby as President

Retrieved on: 
Thursday, February 15, 2024
Acquisition, Weapon, Atmosphere, Technical management, ISR, Growth, Technical, UAS, Government, United States Naval Academy, Interim, Engineering, Grumman, AUVSI, Johns Hopkins University, MTI, Robotics, Software, Northrop Grumman, Management

AgEagle’s Chairman and Interim CEO, Grant Begley, commented, “Bill is a timely and exciting addition to AgEagle’s leadership team. His significant defense industry experience -- particularly in scaling unmanned technology, product development, and business operations -- will be transformative for AgEagle as we enter our next stage of growth. We believe Bill’s deep domain UAS professional successes and industry foresight will contribute as we continue to expand our market footprint and focus on building sustainable shareholder value.”

Key Points: 
  • WICHITA, Kan., Feb. 15, 2024 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class full stack unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, today announces the appointment of William ”Bill” Irby as President, effective February 12, 2024.
  • AgEagle’s Chairman and Interim CEO, Grant Begley, commented, “Bill is a timely and exciting addition to AgEagle’s leadership team.
  • His significant defense industry experience -- particularly in scaling unmanned technology, product development, and business operations -- will be transformative for AgEagle as we enter our next stage of growth.
  • I am eager to leverage my expertise in scaling operations within the global defense and security industry to help drive long-term value for all our stakeholders.”

Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694

Retrieved on: 
Wednesday, December 20, 2023
Health, Neurology, Managed Care, Radiology, Pharmaceutical, Biotechnology, Disease, Positron emission tomography, PET, Brain, Alzheimer's disease, Neurodegenerative disease, Acceleration, MTI, Pharmaceutical industry

Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain.

Key Points: 
  • Meilleur Technologies Inc. (MTI) today announced it has signed an agreement with PharmaLogic Holdings Corporation (“PharmaLogic”) granting PharmaLogic the rights to manufacture fluorine-18 [F18]NAV4694, a next-generation investigational imaging biomarker used in Positron Emission Tomography (PET) imaging studies to assess the status of amyloid plaque in the brain.
  • Amyloid plaques are one of the pathological hallmarks of several neurodegenerative diseases, including Alzheimer’s Disease (AD).
  • Under the terms of its agreement, PharmaLogic will manufacture [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.
  • “We are delighted that the NAV4694 clinical and research program will be supported by Pharmalogic's extensive PET manufacturing and dispensing expertise,” said Rick Hiatt, President and CEO of Meilleur Technologies, Inc. “Meilleur is focused on enabling acceleration of technologies that have the potential to advance the fight against debilitating neurodegenerative disease.

MedTech Innovator Crowns MicroTransponder and Mirai Medical Among its Top Innovators of 2023

Retrieved on: 
Friday, November 17, 2023
Research, Medical Devices, Surgery, Hospitals, FDA, Health Technology, Biotechnology, Health, Science, Oncology, Yee, Corporation, Running, Patient, Stroke, MTI, Medtech, Q&A, Conference, Standard of care, Johnson & Johnson, Cancer, Prize, Pharmaceutical industry, Grand

MedTech Innovator (MTI), the world’s largest accelerator of medical devices, today announced that MicroTransponder won the inaugural 2023 Mid-Stage Grand Prize competition, and Mirai Medical won the 2023 Value Award during the MedTech Strategist Innovation Summit in San Francisco .

Key Points: 
  • MedTech Innovator (MTI), the world’s largest accelerator of medical devices, today announced that MicroTransponder won the inaugural 2023 Mid-Stage Grand Prize competition, and Mirai Medical won the 2023 Value Award during the MedTech Strategist Innovation Summit in San Francisco .
  • The 2023 cohort was selected from over 1,100 applicants, receiving mentorship, resources, access to industry stakeholders, industry visibility, and over $800,000 in awards.
  • StrokeDX was crowned the 2023 Early Stage Grand Prize winner after the audience vote on October 10, 2023, at AdvaMed’s The MedTech Conference.
  • MicroTransponder received the largest MedTech Strategist live audience vote on November 15, winning the $200,000 Grand Prize for its transformative stroke treatment technology.

Celgard and Senior Settle Their Global Litigations

Retrieved on: 
Thursday, November 16, 2023
Senior, MTI, Intellectual property, District court, LP, Polypore

CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.

Key Points: 
  • CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.
  • In the public California District Court and UK litigation filings:
    Celgard voluntarily dismissed all claims against the Senior defendants asserted in its Sixth Amended Complaint in the California District Court.
  • Also, the Senior defendants voluntarily dismissed all counterclaims against Celgard and Polypore.
  • Earlier, Celgard announced the successful outcome of the Targray ( See Release ), MTI ( See Release ) and Farasis cases ( See Release ).

Celgard and Senior Settle Their Global Litigations

Retrieved on: 
Thursday, November 16, 2023
Senior, MTI, Intellectual property, District court, LP, Polypore

CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.

Key Points: 
  • CHARLOTTE, N.C., Nov. 16, 2023 /PRNewswire/ -- Celgard, LLC (Celgard), a subsidiary of Polypore International, LP, (Polypore) settled its litigations against Shenzhen Senior Technology Material Co. Ltd.  (Senior China) and several United States defendants in the United States District Court for the Northern District of California and against Senior China in the United Kingdom (UK), and Senior China's litigations against Celgard.
  • In the public California District Court and UK litigation filings:
    Celgard voluntarily dismissed all claims against the Senior defendants asserted in its Sixth Amended Complaint in the California District Court.
  • Also, the Senior defendants voluntarily dismissed all counterclaims against Celgard and Polypore.
  • Earlier, Celgard announced the successful outcome of the Targray ( See Release ), MTI ( See Release ) and Farasis cases ( See Release ).

Minerals Technologies Reports Third Quarter Loss Per Share of $0.59, or Earnings Per Share of $1.49 Excluding One Time Charges Associated with Barretts Minerals Inc.

Retrieved on: 
Thursday, October 26, 2023
MTX, NYSE, BMI, Operation, Consumer, History, Share repurchase, Biophysical environment, MTI, Growth, Household, Bankruptcy, Personal care, Chapter 11, Title 11, United States Code, Micro Engineering Solutions, Management, Maple syrup, Retail

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today reported diluted earnings per share of $1.49 for the third quarter ended October 1, 2023, excluding $85 million of special items associated with BMI’s bankruptcy. Reported loss per share was $0.59.

Key Points: 
  • Operating income excluding special items was $77 million, up 9 percent sequentially and 15 percent above the prior year.
  • Operating margin excluding special items was 14.1 percent, a 130 basis point improvement sequentially and a 170 basis point improvement year-over-year.
  • Consumer & Specialties segment sales were $291 million in the third quarter, up 2 percent over the prior year.
  • Minerals Technologies will host a conference call tomorrow, October 27, 2023, at 11 a.m. Eastern Time.

Moomoo Discusses 0DTE at the TradersExpo in Orlando, Florida on Oct 29

Retrieved on: 
Thursday, October 26, 2023
History, Zacks, PALO, MTI, Nightclub, Life insurance, Muumuu

PALO ALTO, Calif., Oct. 26, 2023 /PRNewswire/ -- Moomoo Technologies Inc. ("MTI") announced today that the company will present at the TradersExpo in Orlando, Florida from Oct. 29 to Oct. 31.

Key Points: 
  • PALO ALTO, Calif., Oct. 26, 2023 /PRNewswire/ -- Moomoo Technologies Inc. ("MTI") announced today that the company will present at the TradersExpo in Orlando, Florida from Oct. 29 to Oct. 31.
  • 0DTE options trading has increased in popularity over the last few years and traders are eager to know more about 0DTE options and how they work.
  • Zacks will also discuss current and future options trading trends and how to utilize moomoo App tools to understand the market better.
  • Zacks will explain what 0DTE options are, how they work, their history, and their similarities and differences from long-dated options.

Minerals Technologies Announces Increase in Quarterly Dividend and Initiation of New Share Repurchase Program

Retrieved on: 
Wednesday, October 18, 2023
History, Growth, MTX, Share repurchase, NYSE, MTI, Management

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced an increase of its regular quarterly dividend to $0.10 per share on the Company’s common stock.

Key Points: 
  • NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced an increase of its regular quarterly dividend to $0.10 per share on the Company’s common stock.
  • This is an increase of $0.05 per share compared to the prior quarterly dividend.
  • In addition, the Board of Directors for MTI has authorized a new, one-year $75 million share repurchase program, effective immediately.
  • "This dividend increase and new share repurchase program is a reflection of the Board of Directors' continued confidence in growth and financial performance of Minerals Technologies," said Douglas T. Dietrich, Chairman and Chief Executive Officer.